+980.6%
CIEN vs MRNA
+516.4%
+464.2%
-49.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.0% | -3.4% | +2.4% | -0.8% |
| 7D | -4.6% | -10.1% | +5.5% | -4.0% |
| 30D | -12.8% | +126.7% | -139.6% | -21.8% |
| 3M | -23.1% | +184.1% | -207.2% | -33.3% |
| 6M | +6.1% | +143.3% | -137.2% | -6.7% |
| YTD | +44.5% | +359.9% | -315.3% | +17.8% |
| 1Y | +176.6% | +454.2% | -277.6% | +120.3% |
| 3Y | +601.0% | +26.0% | +575.0% | +520.2% |
| 5Y | +509.1% | -70.3% | +579.4% | +471.7% |
| All | +980.6% | +516.4% | +464.2% | +731.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling